HOME >> BIOLOGY >> NEWS
NIAID awards grant to rapidly sequence the malaria mosquito genome

The National Institute of Allergy and Infectious Diseases (NIAID) today announced a $9 million award to help reveal the genetic secrets of malaria, a complex disease responsible for up to 3 million deaths worldwide each year. Through the grant to Celera Genomics Group, NIAID has expanded its efforts to determine the genetic blueprint of Anopheles gambiae, a mosquito species that transmits the malaria parasite to people. As part of an international consortium of A. gambiae researchers and genome sequencing centers, Celera scientists will help sequence the mosquito genome and make the information freely available to the scientific community. Celera anticipates completing the project next spring.

Malaria is caused by parasites of the genus Plasmodium. The disease strikes 300 to 500 million people annually, 90 percent of who live in sub-Saharan Africa. More than 40 percent of the world's population lives in areas where malaria naturally occurs.

Malaria parasites undergo a complex life cycle; to thrive and spread they must spend parts of their lives in both humans and mosquitoes. To learn more about how the parasite, mosquitoes and humans interact, researchers will study the Anopheles genome along with the recently deciphered human genome and the soon-to-be-completed DNA sequence of the deadliest malaria parasite, Plasmodium falciparum. The three genome sequences will provide scientists with a unique opportunity to study the natural history of malaria. For the first time, researchers will have the complete genetic information on an infectious organism, its natural host, and the insect that transmits the disease from person to person.

"This initiative will give us the pieces to an incredibly complex puzzle," says NIAID Director Anthony S. Fauci, M.D. "By analyzing and comparing the genomes of all three organisms, researchers will have a wealth of new information for understanding malaria and how it is spread, and for use in developing
'"/>

Contact: Sam Perdue
sp189u@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
8-Aug-2001


Page: 1 2

Related biology news :

1. TIGR and NIAID sign $65 million microbial sequencing contract
2. NIAID unveils bioterrorism research agenda
3. NIAID takes next genome step
4. NIAID launches major step in trial of experimental shingles vaccine
5. NIAID-Supported Scientists Discover Origin Of HIV-1
6. NIAID Scientists Discover HIV Disease-Slowing Mutation
7. NIAID Doctor Successfully Treats Longest Case Of Malaria Infection On Record
8. Chemical engineering grad students will take notable national awards
9. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
10. NSF awards 22 new projects for plant genome research
11. The American Phytopathological Society announces 2004 awards

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIAID awards grant rapidly sequence the malaria mosquito genome

(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: